0RA9 Stock Chart & Stats
€108.40
€0.00(0.00%)
At close: 4:00 PM EDT
€108.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€60.70 - €139.00
Previous CloseN/A
Volume1.88K
Average Volume (3M)4.31K
Market Cap
€8.50B
Enterprise Value€6.57B
Total Cash (Recent Filing)€530.38M
Total Debt (Recent Filing)€45.89M
Price to Earnings (P/E)―
Beta3.54
Next Earnings
Sep 21, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.83
Shares Outstanding87,253,800
10 Day Avg. Volume1,406
30 Day Avg. Volume4,313
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.31
Revenue Forecast (FY)€3.81M
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetLower leverage and a larger equity base improve financial flexibility over the next several months, giving Abivax more capacity to fund development despite its lack of operating profitability.
Focused Lead Drug PlatformA focused oral candidate addressing chronic inflammatory disease can support scalable development and broader platform value if its proposed immunomodulatory mechanism translates across indications.
Potentially Attractive Product EconomicsNear-100% historical gross margins suggest the candidate could have favorable product economics after commercialization, although this potential remains unproven because current revenue is absent.
Bears Say
Persistent Cash BurnSustained negative cash generation means Abivax cannot currently fund research and operations internally, increasing its need for additional capital before a commercial product can generate cash.
Deepening Losses And No RevenueWidening losses combined with zero reported revenue show that the business remains dependent on clinical progress rather than commercial traction, leaving profitability highly contingent on future approval and launch.
Reliance On External FinancingHistorical leverage swings and the absence of product sales indicate reliance on capital raises or restructuring, which can create dilution and funding risk if clinical development requires more cash than expected.
Abivax SA News
0RA9 FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest share price was €60.70 and its highest was €139.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €8.50B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Sep 21, 2026 which is in 19 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on May 22, 2026. The company reported -€0.61 earnings per share for the quarter, beating the consensus estimate of -€0.803 by €0.193.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Overvalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.84.
How many shares outstanding does Abivax SA have?
Abivax SA has 87,253,800 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€0.61 in its last earnings report, beating expectations of -€0.803. Following the earnings report the stock price went up 7.163%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in GB:0RA9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.